Source comparison
The CJC-1295 with DAC Question: Convenience vs Physiology
CJC-1295 with DAC (Drug Affinity Complex) deserves separate discussion because its pharmacokinetic profile is fundamentally different from the other compounds in the sermorelin vs CJC-1295 vs ipamorelin comparison. The DAC modification enables albumin binding,
This comparison does not assign a generated winner or score.
- CJC-1295 with DAC (Drug Affinity Complex) deserves separate discussion because its pharmacokinetic profile is fundamentally different from the other compounds in the sermorelin vs CJC-1295 vs ipamorelin comparison. The DAC modification enables albumin binding, extending the half-life to 6-8 days. This means a single weekly injection produces sustained GHRH receptor activation throughout the entire dosing interval.
- The convenience is undeniable — weekly dosing versus daily or multiple-daily dosing. However, sustained GHRH receptor stimulation produces a different GH pattern than pulsatile stimulation. Instead of discrete GH pulses followed by somatostatin-mediated troughs, CJC-1295 with DAC produces a more continuous GH elevation. Published research suggests this sustained profile can blunt natural GH pulsatility over time and may reduce the somatotroph cells’ responsiveness to GHRH stimulation.
- This has practical implications. The natural pulsatile pattern of GH secretion appears to be important for some of GH’s effects — lipolysis, for example, responds more robustly to pulsatile GH than to constant GH levels. Researchers who prioritize preserving natural pulsatility generally prefer CJC-1295 without DAC (which produces pulses like sermorelin but with improved enzymatic resistance) over the with-DAC version. For researchers studying the downstream effects of GH peptides on body composition, see our peptides for muscle growth and recovery guide.